BCV
ATNM icon

Banque Cantonale Vaudoise’s Actinium Pharmaceuticals ATNM Stock Holding History

Banque Cantonale Vaudoise’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-309
Closed -$1K – 1232
2022
Q2 		$1K Hold
309
– – ﹤0.01% 1261
2022
Q1 		$2K Hold
309
– – ﹤0.01% 1264
2021
Q4 		$2K Hold
309
– – ﹤0.01% 1278
2021
Q3 		$3K Buy
+309
New +$2.15K ﹤0.01% 1240

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Banque Cantonale Vaudoise's ATNM Position: Q3 2022 in Review

Banque Cantonale Vaudoise sold out of Actinium Pharmaceuticals (ATNM) in Q3 2022, closing a stake of 309 shares — an estimated $1K sold.

Banque Cantonale Vaudoise first reported a position in ATNM in Q3 2021 and held it in 4 quarters. The position peaked at $3K in Q3 2021. 56 funds tracked by Wall St. Rank hold ATNM as of Q3 2022.

  • Banque Cantonale Vaudoise reported no remaining Actinium Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Banque Cantonale Vaudoise sold 309 Actinium Pharmaceuticals shares in Q3 2022, an estimated $1K.
  • Banque Cantonale Vaudoise first reported a position in Actinium Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • Banque Cantonale Vaudoise's Actinium Pharmaceuticals position peaked at $3K in Q3 2021.
  • 56 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2022.

Based on Banque Cantonale Vaudoise's 13F filing for Q3 2022, filed 17 Oct 2022.